Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges

Jeffrey Glennon, Diane Purper-Ouakil, Mireille Bakker, Alessandro Zuddas, Pieter Hoekstra, Ulrike Schulze, Josefina Castro-Fornieles, Paramala J. Santosh, Celso Arango, Michael Kölch, David Coghill, Itziar Flamarique, Maria J. Penzol, Mandy Wan, Macey Murray, Ian C K Wong, Marina Danckaerts, Olivier Bonnot, Bruno Falissard, Gabriele MasiJörg M. Fegert, Stefano Vicari, Sara Carucci, Ralf W. Dittmann, Jan K. Buitelaar

Research output: Contribution to journalArticle

Abstract

In children and adolescents with conduct disorder (CD), pharmacotherapy is considered when non-pharmacological interventions do not improve symptoms and functional impairment. Risperidone, a second-generation antipsychotic is increasingly prescribed off-label in this indication, but its efficacy and tolerability is poorly studied in CD, especially in young people with normal intelligence. The Paediatric European Risperidone Studies (PERS) include a series of trials to assess short-term efficacy, tolerability and maintenance effects of risperidone in children and adolescents with CD and normal intelligence as well as long-term tolerability in a 2-year pharmacovigilance. In addition to its core studies, secondary PERS analyses will examine moderators of drug effects. As PERS is a large-scale academic project involving a collaborative network of expert centres from different countries, it is expected that results will lead to strengthen the evidence base for the use of risperidone in CD and improve standards of care. Challenging issues faced by the PERS consortium are described to facilitate future developments in paediatric neuropsychopharmacology.

Original languageEnglish
Pages (from-to)1149-1160
Number of pages12
JournalEuropean Child and Adolescent Psychiatry
Volume23
Issue number12
DOIs
Publication statusPublished - Nov 28 2014

Keywords

  • Conduct disorder
  • Pharmacovigilance
  • Psychopharmacology
  • Randomised clinical trials
  • Risperidone

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pediatrics, Perinatology, and Child Health
  • Philosophy
  • Developmental and Educational Psychology

Fingerprint Dive into the research topics of 'Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges'. Together they form a unique fingerprint.

  • Cite this

    Glennon, J., Purper-Ouakil, D., Bakker, M., Zuddas, A., Hoekstra, P., Schulze, U., Castro-Fornieles, J., Santosh, P. J., Arango, C., Kölch, M., Coghill, D., Flamarique, I., Penzol, M. J., Wan, M., Murray, M., Wong, I. C. K., Danckaerts, M., Bonnot, O., Falissard, B., ... Buitelaar, J. K. (2014). Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges. European Child and Adolescent Psychiatry, 23(12), 1149-1160. https://doi.org/10.1007/s00787-013-0498-3